Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Karyopharm Therapeutics (KPTI) Revenue (2016 - 2025)

Karyopharm Therapeutics (KPTI) has disclosed Revenue for 14 consecutive years, with $34.1 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Revenue rose 11.58% year-over-year to $34.1 million, compared with a TTM value of $146.1 million through Dec 2025, up 0.57%, and an annual FY2025 reading of $146.1 million, up 0.57% over the prior year.
  • Revenue was $34.1 million for Q4 2025 at Karyopharm Therapeutics, down from $44.0 million in the prior quarter.
  • Across five years, Revenue topped out at $126.3 million in Q4 2021 and bottomed at $22.6 million in Q2 2021.
  • Average Revenue over 5 years is $40.2 million, with a median of $36.9 million recorded in 2022.
  • The sharpest move saw Revenue surged 259.74% in 2021, then tumbled 73.41% in 2022.
  • Year by year, Revenue stood at $126.3 million in 2021, then crashed by 73.41% to $33.6 million in 2022, then increased by 0.5% to $33.7 million in 2023, then dropped by 9.5% to $30.5 million in 2024, then increased by 11.58% to $34.1 million in 2025.
  • Business Quant data shows Revenue for KPTI at $34.1 million in Q4 2025, $44.0 million in Q3 2025, and $37.9 million in Q2 2025.